![Grünenthal Group](/data/images/public/13560264/13964863/3a2120a5-9c1c-4b4a-8c53-9ec3be0f344d-w_360_h_52.png)
Grünenthal acquires US-company Valinor Pharma and becomes global owner of Movantik®22.7.2024 09:56:23 CEST | Grünenthal Group
Grünenthal acquires the pharmaceutical company Valinor Pharma, further strengthening Grünenthal’s footprint in the United States. With the acquisition, Grünenthal becomes the global owner of Movantik® / Moventig® (naloxegol). Since 2017, Grünenthal has invested more than €2 billion in successful M&A transactions, significantly strengthening its profitability.